GlassScriptPhysician profile
Richard M Carr
NPI 1144223108
$1,896.17
in general payments reported to CMS, 2019-2025
10 companies · $537 in 2025
The $537 reported for 2025 was more than what 85% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $724 · 2020: $109 · 2021: $301 · 2022: $144 · 2023: $44.07 · 2024: $37.03 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $588 · Education: $29.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $588.22 |
| Education | $29.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $584.12 | 2019-2025 | Sublocade |
| Alkermes, INC. | $485.25 | 2019-2023 | Vivitrol |
| Sunovion Pharmaceuticals INC. | $332.65 | 2019 | |
| Gilead Sciences, INC. | $148.45 | 2021-2025 | |
| Axsome Therapeutics, INC. | $141.31 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $124.63 | 2019 | |
| Braeburn INC. | $21.88 | 2025 | Brixadi |
| Vanda Pharmaceuticals INC. | $20.99 | 2025 | Fanapt |
| Scilex Pharmaceuticals INC. | $20.22 | 2021 | |
| Mdd US Operations, LLC | $16.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Carr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.